Molukat

Take one tablet daily in the evening. The tablet should be chewed thoroughly before swallowing. It can be taken with or without food.

Montelukast selectively antagonizes the CysLT1 receptor. The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are potent inflammatory eicosanoids released from various cells including mast cells and eosinophils. These pro-asthmatic mediators bind to CysLT1 receptors in the human airway and on other pro-inflammatory cells, producing airway constriction, bronchial secretion, edema, and eosinophil recruitment. Montelukast inhibits these actions by blocking the receptor.

• Hypersensitivity to the active substance or to any of the excipients.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

In clinical studies, patients have received Montelukast up to 200 mg/day for 22 weeks and in short-term studies, up to 900 mg/day for approximately one week, without clinically important adverse experiences. In case of overdose, standard supportive measures should be taken. It is not known whether Montelukast is dialyzable by peritoneal dialysis or hemodialysis.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known if Montelukast is excreted in human milk; use with caution in nursing mothers.

• Hypersensitivity to the active substance or to any of the excipients.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

In clinical studies, patients have received Montelukast up to 200 mg/day for 22 weeks and in short-term studies, up to 900 mg/day for approximately one week, without clinically important adverse experiences. In case of overdose, standard supportive measures should be taken. It is not known whether Montelukast is dialyzable by peritoneal dialysis or hemodialysis.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known if Montelukast is excreted in human milk; use with caution in nursing mothers.